Lastly, we were underpowered to determine if clinical factors such as glioma grade, IDH mutation status, MGMT promoter methylations status, number of recurrences and treatment history would affect rCBV correlations between the 2 methods but these questions could be addressed in a future larger study. The gene discussed is IDH1; the disease is central nervous system cancer.